Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Alroughani

Showing results (141-150 of 223) with videos related to

Pageof 23
Sort By:
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyPakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Multiple Sclerosis and Related Disorders|March 14, 2020
Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registryEslam Shosha, Abdulla Al Asmi, Eman Nasim, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Pageof 23

Showing results (141-150 of 223) with videos related to

Sort By:
Pageof 23
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyPakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Multiple Sclerosis and Related Disorders|March 14, 2020
Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registryEslam Shosha, Abdulla Al Asmi, Eman Nasim, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Pageof 23